Immunome(IMNM) - 2025 Q1 - Quarterly Results

Financial Performance - As of March 31, 2025, Immunome reported cash, cash equivalents, and marketable securities totaling $317.3 million, including net proceeds of$161.7 million from a financing round in January 2025[9]. - Immunome reported a net loss of $41.6 million for Q1 2025, compared to a net loss of$129.5 million in Q1 2024[9][13]. - Collaboration revenue for Q1 2025 was $2.9 million, up from$1.0 million in Q1 2024[13]. - The total operating expenses for Q1 2025 were $47.6 million, significantly lower than$133.3 million in Q1 2024[13]. - Research and development expenses for Q1 2025 were $36.9 million, with stock-based compensation costs of$2.4 million[9]. - General and administrative expenses for Q1 2025 were $10.7 million, including stock-based compensation expense of$3.3 million[9]. - The weighted-average shares outstanding for Q1 2025 were 79,410,354, compared to 51,544,383 in Q1 2024[13]. Clinical Development - The Phase 3 RINGSIDE Part B study of varegacestat for desmoid tumors completed full enrollment in February 2024, with topline data expected in the second half of 2025[3]. - The Phase 1 clinical trial of IM-1021 began dosing its first patient in February 2025, targeting advanced B-cell lymphomas and solid tumors[4]. - Immunome received IND clearance for IM-3050 in April 2025 and plans to initiate a Phase 1 clinical trial in the second half of 2025[4].